Scalper1 News
Specialty-drug giants and IBD 50 stocks Actavis (ACT) and Valeant Pharmaceuticals International (VRX) were both trading up Thursday morning after the FDA approved both of their bowel-disease drugs late Wednesday. Valeant’s Xifaxan 550 and Actavis’ eluxadoline, now branded Viberzi, were both approved for irritable bowel syndrome with diarrhea, or IBS-D. As IBD reported in our summer drug-approval preview, despite this commonality the drugs are Scalper1 News
Scalper1 News